Drug Profile
Lampalizumab - Genentech
Alternative Names: Anti-complement Factor D antibody; Anti-factor D; FCFD4514S; RG7417; RO 5490249; TNX-234Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Tanox
- Developer Genentech
- Class Anti-inflammatories; Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Complement factor D inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dry age-related macular degeneration
Most Recent Events
- 23 Apr 2019 Roche terminates the phase III CHROMA trial in Dry age-related macular degeneration in USA, Argentina, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Hungary, Italy, Mexico, the Netherlands, Peru, Poland, Slovakia, Spain, Switzerland, and the UK (NCT02247479)
- 21 Aug 2018 Roche terminates the Omaspect phase III trial in Dry age related macular degeneration in USA, Australia, Austria, Belgium, Canada,Denmark, France, Germany, Hungary, Italy, the Netherlands, Peru, Poland, Portugal Slovakia, Spain, Switzerland, Turkey, the United Kingdom (NCT02745119)
- 21 Feb 2018 Discontinued - Phase-III for Dry age-related macular degeneration in Switzerland, Spain, Slovakia, Poland, Netherlands, Italy, Hungary, Germany, France, Denmark, Belgium, Austria, Australia, USA, Portugal, Russia, United Kingdom (Intravitreous)